---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004619"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:29:16.753256+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics raises $1M via convertible note with Ingodwe Trust

## Summary
- Issued 12% simple interest one-year convertible promissory note for $1,000,000 principal.
- Conversion at 10% discount to 10-day VWAP; optional warrant for 50% of conversion shares at 120% of conversion price.
- Proceeds used for working capital; mandatory conversion if public offering occurs before maturity.
- Lender Ingodwe Trust is an accredited investor; securities issued under Rule 506(b) exemption.

## SEC filing metadata
- accession: 0001493152-24-004619
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/0001493152-24-004619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004619
- JSON: https://secwatch.observer/filing/0001493152-24-004619.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004619.txt

## Key facts
- Material Agreements
  Calidi Biotherapeutics, Inc. entered into Convertible Promissory Note Purchase Agreement with Accredited Investor (the Lender) valued at $1,000,000 (effective 2024-01-26).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Accredited Investor (the Lender)
  - Value: $1,000,000
  - Effective: 2024-01-26
  source text: On January 26, 2024, Calidi Biotherapeutics, Inc. (the “Company”) entered into a convertible promissory note purchase agreement (the “Purchase Agreement”) with an Accredited Investor (the “Lender”), for a loan in the principal amount of One Million dollars ($1,000,000), the proceeds of which will be used by the Company for working capital purpose (the “Loan”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/0001493152-24-004619-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.